NCT02289768View on ClinicalTrials.gov

Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses

PHASE3CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Actinic Keratosis
Interventions
DRUG

5-fluorouracil/salicylic acid

DRUG

Vehicle

Trial Locations (14)

10117

Almirall Investigational Site #3, Berlin

13055

Almirall Investigational Site #5, Berlin

13507

Almirall Investigational Site #4, Berlin

42275

Almirall Investigational Site #7, Wuppertal

44791

Almirall Investigational Site #1, Bochum

44803

Almirall Investigational Site #8, Bochum

48249

Almirall Investigational Site #9, Dülmen

53111

Almirall Investigational Site #6, Bonn

56242

Almirall Investigational Site #2, Selters

88045

Almirall Investigational Site #10, Friedrichshafen

LE10 2SE

Almirall Investigational Site #11, Leicester

CW5 5NX

Almirall Investigational Site #12, Nantwich

TR18 4JH

Almirall Investigational Site #13, Penzance

TR19 7HX

Almirall Investigational Site #14, Penzance

Sponsors

Lead Sponsor

Almirall, S.A.
All Listed Sponsors
collaborator

Almirall Hermal GmbH

INDUSTRY

lead

Almirall, S.A.

INDUSTRY

NCT02289768 - Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses | Biotech Hunter | Biotech Hunter